Comparative Pharmacology
Head-to-head clinical analysis: K LEASE versus SLOW K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K LEASE versus SLOW K.
K-LEASE vs SLOW-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement therapy; increases extracellular potassium levels to correct hypokalemia.
Potassium is the major intracellular cation; essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function.
1 tablet (25 mEq) orally 2-4 times daily with meals; maximum 100 mEq/day.
Adults: 600-2400 mg potassium chloride (8-32 mmol K+) orally per day in divided doses, usually 1-2 tablets twice daily. Maximum single dose: 20 mmol. Route: oral. Frequency: 1-4 times daily.
None Documented
None Documented
Not applicable; exogenous potassium is not subject to terminal elimination half-life as it is rapidly redistributed and excreted. Clinical context: the half-life of redistribution is minutes to hours.
Not applicable; potassium is an electrolyte with no defined elimination half-life; distribution half-life ~2-4 hours
Excreted renally as potassium chloride; elimination is 100% renal. No biliary or fecal excretion.
Primarily renal (>90%) as potassium ions; minimal biliary/fecal elimination (<5%)
Category C
Category C
Potassium Supplement
Potassium Supplement